Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.7652W HIGH $2.91
Volume
24.28 K
Value Traded
31.93 K
Short % Float
0.1%
-1.17%Week
+1.61%1 Month
+0.8%3 Month
+2.43%6 Month
-99.83%5 Year
-99.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.19 M
EPS (TTM)
-2.48
P/E Ratio
-
Ent. Value
-5.64 M
Total Shares
4.42 M
Float Shares
3.91 M
Insiders
11.64%
Institutions
35.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KPRX Catalyst Timeline
Dated clinical, regulatory and corporate events for Kiora Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kiora Pharmaceuticals, Inc.
355Total events
15Upcoming
102Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Management ChangeCorporate
Keith J. Lane appointed Executive Vice President of Global Clinical Development and Regulatory Affairs
▲Partnership / LicenseKIO-301FiledCorporate
Licensed South Korean development and commercialization rights for KIO-301 to Chong Kun Dang Pharmaceutical
retinitis pigmentosasource ↗
●Enrollment UpdateKIO-301FiledTrial
Advanced enrollment in Phase 2 ABACUS-2 trial of KIO-301 into higher-dose cohort
late-stage retinitis pigmentosasource ↗
●Enrollment UpdateKIO-104Trial
Continued enrollment in higher-dose cohort of Phase 2 KLARITY trial of KIO-104
macular edema due to retinal inflammationsource ↗
◆Safety Data UpdateKIO-301FiledClinical Data
Predefined safety review after first few patients in higher-dose cohort
late-stage retinitis pigmentosasource ↗
◆Partnership / LicenseKIO-301FiledCorporate
Evaluating potential commercial partner for South Korea
retinitis pigmentosasource ↗
◆Pipeline PrioritizationCorporate
Evaluating potential strategic transactions to expand pipeline
▲Poster PresentationKIO-300Presentation
Poster presentation of KIO-300 preclinical data in epilepsy model at Epilepsy Foundation Pipeline Conference
temporal lobe epilepsysource ↗
▲Enrollment UpdateKIO-301FiledTrial
Enrollment in ABACUS-2 close to 50% completed
retinitis pigmentosasource ↗
◆Management ChangeCorporate
Chief Development Officer Eric J. Daniels to depart on April 17, 2026
▼Equity OfferingCorporate
Closed private placement for up to $24 million led by Perceptive Advisors
▲Enrollment UpdateKIO-301FiledTrial
ABACUS-2 Phase 2 trial received approval to enroll remaining patients in 50 µg dose cohort and clearance to initiate 100 µg dose cohort
retinitis pigmentosasource ↗
▲Enrollment UpdateKIO-104Trial
KLARITY Phase 2 trial cleared all planned safety review checkpoints; patient enrollment ongoing
macular edema due to retinal inflammationsource ↗
▲PublicationKIO-301FiledPresentation
Publication of ABACUS-1 results in Nature Medicine
retinitis pigmentosasource ↗
●Runway Guidance UpdateCorporate
Cash runway into late 2027, beyond anticipated data readouts
◆Enrollment UpdateKIO-104Trial
Continued recruitment and patient dosing in KLARITY Phase 2 trial of KIO-104
retinal inflammationsource ↗
◆Enrollment UpdateKIO-301FiledTrial
Continued recruitment and patient dosing in ABACUS-2 Phase 2 trial of KIO-301
retinitis pigmentosasource ↗
▲Runway Guidance UpdateCorporate
Cash runway maintained into late 2027, beyond anticipated data readouts
▲Milestone PaymentKIO-301FiledCorporate
Received $1.2 million in reimbursed R&D expenses from Tha for KIO-301 activities in Q2 2025
▲First Patient DosedKIO-104Trial
First patient expected to be enrolled in KLARITY in Q2 2025
retinal inflammationsource ↗
◆Trial InitiationKIO-104Trial
Plan to initiate Phase 2 CLARITY study early next year
retinal inflammatory diseasessource ↗
▲Partnership / LicenseKIO-301FiledCorporate
Exclusive option agreement with Senju for KIO-301 in Asia
retinal diseasessource ↗
●Poster PresentationKIO-104Presentation
Preclinical data on KIO-104 presented at ARVO 2025
inflammatory and proliferative retinal diseasessource ↗
●Quarterly UpdateCorporate
Q1 2025 financial results reported; cash runway extended into late 2027
▲Trial InitiationKIO-104Trial
Initiated KLARITY Phase 2 trial of KIO-104 for retinal inflammation
retinal inflammationsource ↗
▲Patent GrantedKIO-104IP / Competition
Patent granted for KIO-104 extending market exclusivity into 2043
ocular inflammatory diseasessource ↗
▲Partnership / LicenseKIO-301FiledCorporate
Option agreement with Senju for KIO-301 in Asia
retinitis pigmentosasource ↗
▲Trial InitiationKIO-301FiledTrial
Initiated ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa
retinitis pigmentosasource ↗
▲First Patient DosedKIO-104Trial
First patient dosing expected in Q2 2025 for KLARITY
retinal inflammationsource ↗
◆Full ResultsKIO-301FiledClinical Data
Full data from Phase 2 ABACUS-2 trial of KIO-301 expected in Q2 2025
retinitis pigmentosasource ↗
▲Trial InitiationKIO-104Trial
Approval to initiate KLARITY Phase 2 trial of KIO-104
retinal inflammationsource ↗
▲Trial InitiationKIO-301FiledTrial
Approval to initiate ABACUS-2 Phase 2 trial of KIO-301
retinitis pigmentosasource ↗
◆First Patient DosedKIO-301FiledTrial
First patient dosing expected to begin next year (2025) following validation of functional vision endpoints
retinitis pigmentosasource ↗
▲Trial InitiationKIO-301FiledTrial
ABACUS-2 Phase 2 trial approved to initiate
retinitis pigmentosasource ↗
●Enrollment UpdateKIO-301FiledTrial
Patient enrollment ongoing in functional endpoint study as on-ramp to ABACUS-2
retinitis pigmentosasource ↗
▲Milestone PaymentKIO-301FiledCorporate
Received $1.8 million in reimbursed Q4 2024 R&D expenses from Laboratoires Théa
▲First Patient DosedKIO-104Trial
First patient dosed in KLARITY Phase 2 trial of KIO-104
macular edema due to retinal inflammationsource ↗
▲Partnership / LicenseKIO-301FiledCorporate
Option agreement with Senju Pharmaceutical for KIO-301 in Asian markets
●Preclinical PoCKIO-300Preclinical
Preclinical ex vivo proof of concept for KIO-300 in epilepsy
epilepsysource ↗
▲Enrollment UpdateKIO-104Trial
Cleared early planned safety review checkpoint
macular edema due to retinal inflammationsource ↗
◆Trial InitiationKIO-301FiledTrial
Plan to initiate Phase 2 ABACUS-2 trial later this year
retinitis pigmentosasource ↗
Past FDA Catalysts and PDUFA Decisions
How KPRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | KIO-301 | Phase 1b topline data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$67M
Pipeline Value
Undervalued
Valuation Signal
4
Drugs Scored
5.9x
rNPV / MCap
Top 41%
Micro Cap(rank 270 of 658)
Percentile Rank
Kiora Pharmaceuticals, Inc. faces pipeline headwinds (39/100), with $266M risk-adjusted pipeline value, led by KIO-104 in Macular Edema (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KIO-104 Small moleculeNCT06825702 | Macular Edema | Phase 2 | RECRUITING | 28 | Dec 1, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every KPRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| KIO-301 | retinitis pigmentosa | Phase 2 | 2024-03-25 | Positive results from the ABACUS-1 study indicate the potential efficacy and safety of KIO-301 in treating retinitis pigmentosa.Read More | Kiora Pharmaceuticals Reports 2023 Results Continues to Advance Pipeline of Treatments for Rare Retinal Diseases Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, CaliforniaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Tosca MelissaOfficer (CFO) | Disposition | -911 26,064 held | $2.66 | 07/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KPRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 0 % | 1.15 M | 438.47 K |
KPRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KPRX ranks across every disease it competes in
Competitive Position is a premium feature
See how KPRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKPRX News
KPRXKiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Kiora Pharmaceuticals has appointed Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs. With over 20 years of experience in ophthalmic drug development, Lane will oversee clinical strategies and regulatory approvals for Kiora's pipeline, including KIO-301 for retinitis pigmentosa. His previous role involved managing numerous ophthalmic trials, enhancing Kiora's capabilities in addressing vision-threatening diseases.
Read more →KPRXKiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation
Kiora Pharmaceuticals has licensed the rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation in South Korea. This agreement includes a $1 million upfront payment and potential royalties on future sales. KIO-301 is designed to restore light sensitivity in patients with retinitis pigmentosa, a rare inherited retinal disease. CKD will manage development and commercialization efforts in South Korea.
Read more →KPRXKiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Kiora Pharmaceuticals reported its Q2 2026 financial results, highlighting advancements in its clinical trials for retinal diseases. The company is progressing in the Phase 2 ABACUS-2 and KLARITY trials, with strong patient demand noted. Kiora also secured a private placement to bolster its financial position, ensuring operational funding into late 2028.
Read more →KPRXKiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the Piper Sandler Virtual Ophthalmology Symposium on July 9, 2026. The event will feature an investor fireside chat, which will be accessible live and via replay for 90 days. Kiora is advancing therapies for retinal diseases, including KIO-301 for retinitis pigmentosa and KIO-104 for macular edema.
Read more →KPRXKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals presented preclinical data at the Epilepsy Foundation Pipeline Conference, showing that KIO-300 effectively suppressed seizure activity in a temporal lobe epilepsy model. The results indicate significant reductions in epileptiform activity, suggesting the drug's potential for broader neurological applications. Kiora aims to explore further therapeutic uses of KIO-300 beyond its current focus on vision restoration.
Read more →KPRXKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity
Kiora Pharmaceuticals has announced positive preclinical results at the Epilepsy Foundation Pipeline Conference regarding its ion channel modulator, KIO-300. The data showed that KIO-300 significantly suppressed seizure activity in a temporal lobe epilepsy model, with effects beginning 42 minutes post-treatment and persisting during follow-up periods. This suggests a promising therapeutic potential for KIO-300 beyond its initial applications in ophthalmology, indicating possible uses in treating epilepsy and other neurological disorders.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Kiora Pharmaceuticals has reported positive first-quarter financial results for 2026 and updates on its clinical pipeline focusing on treatments for retinal diseases. The company sees strong patient enrollment in the Phase 2 ABACUS-2 study of KIO-301 and has validated its potential through a publication in Nature Medicine. Significant progress is also noted for the KLARITY study regarding KIO-104, with a pre-defined safety review upcoming. Moreover, Kiora has secured additional funding from a strategic equity financing, enhancing its operational runway into late 2028.
Read more →KPRXKiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
Kiora Pharmaceuticals announced the publication of its Phase 1 ABACUS-1 study results for KIO-301 in Nature Medicine, demonstrating safety and feasibility in patients with retinitis pigmentosa. The company has initiated a Phase 2 trial, ABACUS-2, to evaluate higher doses and functional visual improvements. The publication highlights the need for further studies to confirm long-term benefits.
Read more →KPRX▲ +6.9%on this news· ran to +42% by day 1
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
Kiora Pharmaceuticals announced a private placement that could raise up to $24 million, led by Perceptive Advisors and ADAR1 Capital Management. The funding includes $5 million upfront and up to $19 million from milestone-based warrants. Proceeds will support corporate operations and R&D. The transaction closed on April 6, 2026.
Read more →KPRXKiora Pharmaceuticals Announces Management Team Changes
Kiora Pharmaceuticals announced management changes with the departure of Chief Development Officer Eric J. Daniels, M.D., MBA, effective April 17, 2026. The company expressed gratitude for his contributions while initiating a search for a successor. Kiora remains dedicated to its pipeline aimed at treating retinal diseases, with ongoing clinical trials KIO-301 and KIO-104 showing positive advancements in patient enrollment. The company continues to receive approvals for clinical trial progression, indicating a forward momentum in development.
Read more →KPRXKiora Pharmaceuticals Announces Private Placement for Up to $24 Million led by Perceptive Advisors
Kiora Pharmaceuticals announced the closure of a private placement providing up to $24 million in gross proceeds, with $5 million received upfront and the remaining contingent on milestone-based warrants. The company intends to utilize these funds for general corporate purposes, including strategic business development and research efforts. The private placement involved the sale of common stock and warrants, with significant investors being Perceptive Advisors and ADAR1 Capital Management. This financial boost is expected to facilitate Kiora's ongoing development of therapies for retinal diseases.
Read more →KPRXKiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials Encinitas, California
Kiora Pharmaceuticals has reported its financial results for Q4 and full year 2025, detailing the advancement of its retinal disease treatments. The company has commenced two active Phase 2 clinical trials, with KIO-301 and KIO-104 both in patient dosing stages. Despite ending the year with a solid cash reserve that extends operations into late 2027, Kiora also faced a significant net loss partially due to an impairment charge. The firm is optimistic about its partnerships and pipeline progression, aiming for initial clinical data readouts in 2027.
Read more →KPRXKiora Pharmaceuticals Reports Third Quarter 2025 Results Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
Kiora Pharmaceuticals (NASDAQ: KPRX) has reported its third-quarter 2025 financial results, highlighting advancements in its clinical pipeline for retinal diseases. The company is currently conducting two actively enrolling Phase 2 clinical trials, KLARITY and ABACUS-2, aimed at treating retinal inflammation and retinitis pigmentosa. Kiora ended the quarter with $19.4 million in cash and reported a small net income, a significant improvement from the previous year's losses. The firm's ongoing financial management and collaborations are set to support its development efforts through to late 2027.
Read more →KPRXKiora Pharmaceuticals Reports Second Quarter 2025 Results Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases Encinitas, California
Kiora Pharmaceuticals has reported its financial results for Q2 2025, highlighting advancements in its therapeutic pipeline for retinal diseases. The company has initiated two Phase 2 clinical trials, KLARITY and ABACUS-2, targeting retinal inflammation and vision restoration, respectively. Kiora also strengthened the market exclusivity of KIO-104 and entered a partnership with Senju Pharmaceutical that could yield substantial financial benefits. Despite these advancements, Kiora continues to incur losses, reporting a net loss consistent with prior periods.
Read more →KPRX▲ +36.8%on this news
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
Kiora Pharmaceuticals announced a partnership with Senju Pharmaceutical, granting Senju an exclusive option for the development and commercialization of KIO-301 for retinal diseases across key Asian markets. The agreement has a total potential value of $110 million, including an immediate $1.25 million option fee. KIO-301 is currently in Phase 2 trials and aims to offer therapeutic options for inherited retinal diseases, particularly retinitis pigmentosa. This deal is expected to enhance Kiora's financial stability and extend the commercial reach of KIO-301.
Read more →KPRXKiora Pharmaceuticals Reports First Quarter Results Initiating Two Phase 2 Trials for Treatment of Retinal Diseases Cash and Short-term Investments Expected to Fund Operations into Late 2027 Encinitas, California
Kiora Pharmaceuticals has reported its first quarter results for 2025, announcing the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301, targeting retinal diseases. The company's cash and short-term investments are expected to fund operations until late 2027, providing a robust financial runway. While Kiora experienced a net loss this quarter, the approval for new trials and positive preclinical data strengthen its position in the field of retinal therapeutics. Ongoing patient enrollment and collaborations may further enhance the company's prospects.
Read more →KPRX▼ -5%on this news
Kiora Pharmaceuticals Reports 2024 Results Retinal Disease Drug Development Pipeline Continues to Advance Cash and Short-term Investments Expected to Fund Operations into 2027
Kiora Pharmaceuticals has announced positive developments in its retinal disease drug pipeline, including the initiation of two Phase 2 clinical trials for KIO-104 and KIO-301. The company ended 2024 with $26.8 million in cash, which is projected to fund operations until 2027. These trials aim to address important retinal disorders, with initial data expected in 2026. Despite a reported net loss in Q4 2024, the company is strategically positioned to advance its therapeutic candidates.
Read more →KPRXKiora Pharmaceuticals Reports Third Quarter Results Retinal Disease Pipeline Advancing Two Phase 2 Studies Encinitas, California
Kiora Pharmaceuticals reported its financial results for Q3 2024, highlighting advancements in its retinal disease pipeline, including two Phase 2 studies. The company has received approval to begin the ABACUS-2 trial for KIO-301 and is finalizing plans for the KLARITY trial for KIO-104, which targets multiple retinal inflammatory diseases. Kiora ended the quarter with $29 million in cash, indicating a strong financial position to support ongoing developments. The company anticipates increased research and development expenses as it begins patient enrollment for these studies.
Read more →KPRXDocument Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa Encinitas, California
Kiora Pharmaceuticals has announced the receipt of Investigational New Drug approval to start the ABACUS-2 Phase 2 clinical trial for KIO-301, a treatment aimed at restoring vision in patients with retinitis pigmentosa. This trial will investigate the safety and efficacy of KIO-301 in a multi-center setup across Australia and enroll 36 patients. Notably, KIO-301 is a small molecule that activates in the presence of light, providing potential vision restoration regardless of individual gene mutations. The trial aims to validate breakthrough functional vision endpoints essential for subsequent registration studies in major regions including the US and Europe.
Read more →KPRXKiora Pharmaceuticals Reports Second Quarter Results Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies Encinitas, California
Kiora Pharmaceuticals has reported its second-quarter results as it advances its pipeline targeting retinal diseases. The company is set to initiate two Phase 2 clinical trials for its innovative small molecules, KIO-301 and KIO-104. Kiora maintains a solid cash position, aiming for a runway through 2027, facilitating these developments. Notably, Kiora received Orphan Medicinal Product Designation from the EMA, which could bolster its position in the market. However, the company still faces financial challenges, including a net loss in the recent quarter.
Read more →About Kiora Pharmaceuticals, Inc.
Headquarters169 SAXONY RD., ENCINITAS, CA, 92024
BIOPHARMAWATCH ELITE PLUS
Trade the next KPRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime